Gilead Sciences Inc. faces a challenging trading day as shares drop significantly.
Gilead Sciences Inc. (NASDAQ:GILD) saw its stock price decline by 2.24% in today's trading session, closing at CA$144.20. This drop comes amid ongoing concerns about the company's earnings outlook and competitive pressures in the pharmaceutical sector.
Advertisement
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$184.82B
Div. yield
2.13%
Div. / share
$3.22
52W high
$154.51
52W low
$109.70
1W change
-1.46%
Beta
0.35
Analyst Price Targets
Based on 30 analysts covering GILD · as of Sep 24, 2026
Wall Street analysts forecast GILD stock price to rise 434.7% over the next 12 months.
Consensus
Buy4.13 / 5.00
Avg. Target
C$158.65
+434.7% Upside
Previously C$158.15 on Sep 17, 2026
Current Price
C$29.67
Last close
Analyst Breakdown (30 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
21.8%
Annualized
90-Day Vol
27.1%
Annualized
Trend (90d)
+37.0%
Annualized drift
90d Mean
C$168.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$154.14 | C$142.99 – C$166.17 |
| 60 trading days | C$161.09 | C$144.85 – C$179.14 |
| 90 trading days | C$168.34 | C$147.81 – C$191.73 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should be cautious as Gilead's stock continues to show signs of weakness, particularly with disappointing earnings projections and a challenging market environment.
Gilead's EPS projected to decline by 105.9% this fiscal year.
The consensus earnings estimate for Gilead is currently set at -$0.48 per share, reflecting significant challenges in maintaining profitability.
Bull case
Gilead has made strides in CAR T-cell therapies and has a promising pipeline. If the company can leverage these advancements effectively, it could see long-term growth potential.
Bear case
However, earnings estimates have been downgraded, signaling potential struggles ahead. The projected EPS decline of 105.9% year-over-year raises concerns about Gilead's ability to remain profitable.
Earnings Outlook Dims
Advertisement
Gilead's earnings projections have raised concerns among investors, with the consensus estimate forecasting a significant decline in EPS. The anticipated earnings of -$0.48 for the current fiscal year highlight the company's struggles to maintain profitability amidst competitive pressures.
Market Competition Intensifies
The pharmaceutical landscape is becoming increasingly competitive, particularly in the areas where Gilead operates. As new therapies emerge and competitors enhance their offerings, Gilead may find it challenging to sustain its market position, contributing to today's stock decline.
Investor Sentiment Wavers
Investor sentiment towards Gilead has been affected by the recent earnings estimates and market dynamics. The company's Zacks Rank of #3 (Hold) reflects a cautious outlook, indicating that investors may want to reassess their positions in light of the current challenges.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
